FDA-Approved Treatments
Current approved therapies — what they are, who makes them, and what to ask your doctor.
Approved October 2023 for moderate-to-severe HS. Dual IL-17A/F inhibitor. ~48–54% achieving IHS4-55 response at week 16 — outperforming adalimumab in head-to-head data.
Approved for moderate-to-severe HS (2023). Monthly dosing after loading. ~45% achieving IHS4-55 at 16 weeks.
First FDA-approved biologic for HS (2015). ~50–60% achieve HiSCR at 12 weeks. Multiple biosimilars now available.
Community Feed
What patients and caregivers are saying about Hidradenitis Suppurativa
Join the Hidradenitis Suppurativa community discussion on /pulse — share your experience, ask questions, or post research you've found.
Go to Pulse →CiteYourSource Arena ⚡
Fact-checked debates about Hidradenitis Suppurativa — cite your source, AI scores your claim
Back it up with sources. Our AI scores your claim for factual accuracy — 0 to 100. Top scorers appear on the leaderboard.
Enter the Arena →Diagnosed with HS? Here's what the first year should look like.
Look for a dermatologist who is a member of the HS Foundation (hs-foundation.org) or lists HS as a subspecialty. Academic centers with dedicated HS clinics provide the most comprehensive care.
Ask specifically about adalimumab (Humira or biosimilar), Bimzelx, or Cosentyx. These are FDA-approved specifically for HS and have much stronger evidence than antibiotic monotherapy.
Surgery is underused and often curative for localized Stage 2–3 HS. De-roofing tunnels eliminates affected follicular structures. Surgery + biologic maintenance is the gold standard for advanced disease.
Get Hidradenitis Suppurativa Research Updates — Personalized to Your Situation
Weekly updates from NIH, FDA, and ClinicalTrials.gov. Tell us about your situation and we'll filter what's most relevant for you. Free. No spam.
Frequently Asked Questions
Real questions from patients and caregivers — answered in plain English.